Home / Pharma News

Pharma News

Actavis to acquire generics from Akorn

US generics major Actavis announced on 17 April 2014 that it had made a deal with Akorn and Hi-Tech Pharmacal (Hi-Tech) to buy five of their products.

UK court invalidates Herceptin patents

A High Court in the UK has overturned two key patents on Roche’s breast cancer blockbuster Herceptin (trastuzumab).

Actavis buys Thai generics company

US generics major Actavis has acquired Silom Medical Company, a privately held generics firm focused on developing and marketing therapies in Thailand, for around US$100 million in cash.

US FTC hopes to collect US$1 billion from pay-for-delay settlement

The US Federal Trade Commission (FTC) is looking to collect more than US$1 billion from a settlement with pharmaceutical companies it has sued for their part in what the FTC terms ‘pay-for-delay’ deals.

Anticompetitive practices come under scrutiny in Australia

The Australian Competition and Consumer Commission (ACCC) has started proceedings in the Federal Court against Pfizer Australia (Pfizer) alleging that offers made by Pfizer to pharmacies before the expiry of the patents for its blockbuster cholesterol-lowering drug Liptor (atorvastatin) were anticompetitive.

Actavis to acquire specialty drugmaker Forest Labs

US-based generic drugmaker Actavis is set to grow even bigger, with the acquisition of US-based Forest Laboratories (Forest Labs), according to an announcement by the companies on 18 February 2014.

Actavis sells interest in China

US generic drugmaker Actavis has sold its interest in its Chinese subsidiary based in Foshan, Guangdong, to Zhejiang Chiral Medicine Chemicals. Actavis, the second biggest generic drugmaker by market capitalization, intends to continue further commercial operations in China in collaboration with its preferred business partners.

Top 10 most read GaBI Online articles in 2013

2013 was a busy year with lots of developments in the biosimilars arena, ranging from revision of regulatory guidelines to new biosimilar approvals. Biosimilars remain the hot topic of the year for GaBI Online during 2013 and in fact all 10 of the most read articles concern biosimilars.

Aurobindo to acquire seven generics businesses from Actavis

US generics maker Actavis and Indian generics maker Aurobindo Pharma (Aurobindo) announced on 17 January 2014 the signing of an offer for Aurobindo to acquire generics commercial operations in seven markets in Western Europe from Actavis.

Pfizer’s generics business up for grabs

In 2013, Pfizer, the world’s largest drugmaker, split its business into two brand-name drug units and a generics business. Now it seems the generics unit, or its ‘established products’ unit, is being circled for a potential takeover bid.

Generics News Research General


Biosimilars News Research General